Major capital increase for Camel-IDS - 15/11/18.

Posted on 13-12-2018

37 million euros, this is the amount of the major capital increase announced on November 15, 2018 by Camel-IDS.

Camel-IDS is a spin-off based in Brussels which develops innovative drugs in the field of the radioimmunotherapy.

This funding represents one of the most important financing operations for a young European company in the field of life sciences and will allow the company, among other things, to develop the clinical tests.